{"id":812217,"date":"2025-02-12T13:03:22","date_gmt":"2025-02-12T18:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/"},"modified":"2025-02-12T13:03:22","modified_gmt":"2025-02-12T18:03:22","slug":"agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/","title":{"rendered":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting"},"content":{"rendered":"

<\/p>\n

Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting<\/b><\/p>\n

LEXINGTON, Mass.–(BUSINESS WIRE<\/a>)–
\nAgenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT\/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT\/BAL) in combination with MiNK Therapeutics\u2019 iNKT cell therapy, AgenT-797, in patients with refractory (2L+) gastric cancer (NCT06251973<\/a>). A Trial-in-Progress (TiP) poster will feature data from the ongoing Phase 1\/2 study of BOT\/BAL in first-line MSS colorectal cancer (NCT05627635<\/a>).<\/p>\n

Presentation Details:<\/b><\/p>\n

Abstract Title:<\/b> First-line botensilimab and balstilimab optimization in microsatellite stable colorectal cancer (MSS-CRC) without liver metastasis (BBOpCo)<\/p>\n

Session<\/b>: Poster Session A<\/p>\n

Session Date and Time: <\/b>Monday, February 24th<\/sup>, 1:45-4:45 p.m. PST<\/p>\n

Abstract Title:<\/b> Biomarker analysis from phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)<\/p>\n

Session<\/b>: Proffered Papers, Session 2<\/p>\n

Session Date and Time:<\/b> Tuesday, February 25th<\/sup>, 1:00-1:45 p.m. PST<\/p>\n

About Agenus<\/b><\/p>\n

\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.<\/p>\n

About Botensilimab (BOT)<\/b><\/p>\n

\nBotensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to \u201ccold\u201d tumors which generally respond poorly to standard of care or are refractory to conventional PD-1\/CTLA-4 therapies and investigational therapies.<\/p>\n

\nApproximately 1,100 patients have been treated with botensilimab and\/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus\u2019 investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov<\/a> with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.<\/p>\n

About Balstilimab (BAL)<\/b><\/p>\n

\nBalstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.<\/p>\n

About AgenT-797<\/b><\/p>\n

\nAgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy, leveraging a unique innate immune cell type that serves as a master regulator of both innate and adaptive immunity. iNKTs combine the cytotoxic capabilities of natural killer (NK) cells with the adaptive memory of T cells, enabling them to elicit a broad range of immune responses in a pathogen-agnostic manner.<\/p>\n

\nAgenT-797 is a scalable, \u201coff-the-shelf\u201d cell therapy product, manufactured by MiNK Therapeutics in Lexington, MA, to deliver transformative treatment solutions to patients.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250212738181\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/b>
917-362-1370
\n
investor@agenusbio.com<\/a><\/p>\n

Media
\n<\/b>
510-323-5188
\n
communications@agenusbio.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT\/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT\/BAL) in combination with MiNK Therapeutics\u2019 iNKT cell therapy, AgenT-797, in patients with refractory (2L+) gastric cancer (NCT06251973). A Trial-in-Progress (TiP) poster will feature data from the ongoing Phase 1\/2 study of BOT\/BAL in first-line MSS colorectal cancer (NCT05627635). Presentation Details: Abstract Title: First-line botensilimab and balstilimab … <\/p>\n

Continue reading “Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812217","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAgenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT\/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT\/BAL) in combination with MiNK Therapeutics\u2019 iNKT cell therapy, AgenT-797, in patients with refractory (2L+) gastric cancer (NCT06251973). A Trial-in-Progress (TiP) poster will feature data from the ongoing Phase 1\/2 study of BOT\/BAL in first-line MSS colorectal cancer (NCT05627635). Presentation Details: Abstract Title: First-line botensilimab and balstilimab … Continue reading "Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T18:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus\u2019 BOT\\\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting\",\"datePublished\":\"2025-02-12T18:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/\"},\"wordCount\":795,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/\",\"name\":\"Agenus\u2019 BOT\\\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-12T18:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus\u2019 BOT\\\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk","og_description":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT\/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT\/BAL) in combination with MiNK Therapeutics\u2019 iNKT cell therapy, AgenT-797, in patients with refractory (2L+) gastric cancer (NCT06251973). A Trial-in-Progress (TiP) poster will feature data from the ongoing Phase 1\/2 study of BOT\/BAL in first-line MSS colorectal cancer (NCT05627635). Presentation Details: Abstract Title: First-line botensilimab and balstilimab … Continue reading \"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-12T18:03:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting","datePublished":"2025-02-12T18:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/"},"wordCount":795,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/","name":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-12T18:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212738181r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-bot-bal-selected-for-two-presentations-at-upcoming-aacr-io-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus\u2019 BOT\/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812217"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812217\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}